Dermatology Annual Skin-Cancer Screening Recall: 5.2% Response on 600 Patients

The challenge

Coastal Dermatology Associates ran a high-volume practice in a sun-belt market where skin-cancer screening should have been a steady-state recurring revenue line. Their EMR showed 2,400 patients with active charts but only 1,800 had been seen in the past 14 months. The 600-patient gap represented annual full-body screenings that had drifted past their schedule — and in a Florida market, that's a clinical concern as much as a revenue gap.

Existing recall was the EMR's automated email plus an SMS reminder 30 days post-due. Open rates on email ran 19%, click 1.6%, and bookings tracked to the recall blast were under 20 per quarter from a 600-patient pool. The senior partner had pushed for a phone-call recall, but the front-desk team was already at 90% utilization on inbound and same-day rescheduling — adding 600 outbound dials wasn't realistic.

The owner-derms wanted three things: (1) a way to interrupt the email-fatigue cycle for older Florida patients (median age 62 in this segment), (2) a recall that surfaced the patients most at risk for actually skipping the screening (long-gap, high-mole-burden histories), and (3) something they could deploy quarterly without a labor surge.

The PostKnock approach

Playbook used: Annual Wellness Recall

We deployed PostKnock's Annual Wellness Recall playbook configured for dermatology, with creative tuned for clinical seriousness — no "glow up" cosmetic-derm framing, no offers, no discounts. Skin-cancer screening is a category where a discount actually undermines trust. The 600-patient list was segmented by risk profile: high-risk (history of biopsy or family history, 180), standard-risk (>50, fair-skinned, 280), and lower-risk (<50, no flags, 140).

Wave 1 went as a 6x9 postcard with a clinically-toned headline ('Your annual skin check is due') and a personalized line referencing the patient's last visit date. The card included a QR code linking to the practice's online booking calendar (filtered to screening-only slots) and a phone number. No discount, no "limited time" — just the medical recall framed appropriately. The high-risk segment received a slightly more direct version with a 'we recommend not waiting' line approved by the senior partner.

Wave 2 dropped at week 4 only to the segments that hadn't booked, with a different creative angle — a stat-driven layout citing Florida skin-cancer rates and a shorter copy block. We did not deploy phone follow-up; the owner's labor constraint was real. Total: ~960 pieces (Wave 1 full 600 + Wave 2 ~360 to non-bookers), 6-week campaign. The campaign was designed to be re-runnable on a rolling cohort each quarter.

Campaign timeline

Week 0

EMR export, 3-tier risk segmentation, copy review with senior partner.

Week 1

Wave 1 drops (600 cards). High-risk segment gets stronger CTA.

Week 2-3

Bookings flow. 19 screenings scheduled.

Week 4

Wave 2 drops (~360 cards) to non-responders. Stat-driven creative.

Week 5-6

Tail bookings. 12 incremental screenings.

Week 7

Final tally: 31 booked. Two suspicious lesions detected; one referred to MOHS.

Results

Thirty-one booked screenings on 600 unique patients lands at 5.2% — within the 3-6% healthcare recall range, on the higher end because the campaign avoided promotional framing in a category where seriousness reads as trustworthy. Visible revenue is modest by dermatology standards: 31 screenings at $300 average ($9,300, mostly insurance-paid). But the screening tail is what matters — two lesions flagged biopsy, one referred to MOHS surgery (averaging $2,200-$3,800 per case), and four high-mole-burden patients booked into ongoing 6-month surveillance.

Campaign cost ran $3,460 — $576 in postcards (960 at $0.60), $297 in Pro plan, and $2,587 in list-prep + EMR-integration labor. The headline 2.7x ROI on visible revenue understates the campaign — the MOHS referral alone bridges the gap, and the four surveillance patients now generate $1,200/year in recurring screenings each. Year-2 ROI on this same cohort lands closer to 6x without sending another card.

“I asked PostKnock if we could remove the discount and the offer language entirely. They didn't push back. The card felt like a doctor's letter, not a promotion. That's why my patients responded.”

— Senior Partner, Coastal Dermatology (composite illustration)

What we’d do differently

• Removing the discount actually lifted response in this category. Skin-cancer screening is trust-driven; promotional framing reduces credibility. We'd default to no-discount for all dermatology screening recalls.
• Risk-tier segmentation paid off. The high-risk segment booked at 9.4% (17 of 180), the standard at 4.6%, the low-risk at 2.1%. Future campaigns should weight mailing volume toward risk-tier 1-2 and de-prioritize tier 3.
• We should have included a short note about the practice's MOHS capability. The one MOHS referral bumped revenue meaningfully; surfacing the in-house capability could have generated 1-2 additional conversions.